Japan’s Ministry of Health, Labour and Welfare has issued a conditional approval to Chugai Pharmaceutical Co. Ltd. ’s first-in-class antibody Hemlibra (emicizumab), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital Factor VIII deficiency (hemophilia A) who have Factor VIII inhibitors.
The product is approved in a range of once-weekly subcutaneous injection formulations from 30mg to 150mg and is awaiting a...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
